An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan; Prednisone and Thalidomide (MPT) Versus Melphalan; Prednisone and Lenalidomide (Revlimid TM) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy